Plus Therapeutics (PSTV) Operating Expenses (2011 - 2026)

Plus Therapeutics (PSTV) has 16 years of Operating Expenses data on file, last reported at $8.1 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $8.1 million, up 77.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.1 million (up 19.49% YoY), and the FY2025 annual result was $20.5 million, changed 0.04% from the prior year.
• Operating Expenses grew to $8.1 million in Q1 2026 per PSTV's latest filing, from $7.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $8.1 million in Q1 2026 and troughed at $2.9 million in Q2 2025.
• A 5-year average of $5.1 million and a median of $5.2 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 98.83% in 2022, then tumbled 41.16% in 2025.
• A 5-year view of Operating Expenses shows it stood at $5.7 million in 2022, then slipped by 9.65% to $5.2 million in 2023, then gained by 2.73% to $5.3 million in 2024, then surged by 33.83% to $7.1 million in 2025, then advanced by 14.6% to $8.1 million in 2026.
• Business Quant data shows PSTV's Operating Expenses at $8.1 million in Q1 2026, $7.1 million in Q4 2025, and $5.9 million in Q3 2025.